NCT04825340View on ClinicalTrials.gov

To Explore a Bridging Index for the Effectiveness of the Clinical Trial

NAUnknownINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

April 16, 2021

Primary Completion Date

March 25, 2022

Study Completion Date

March 25, 2022

Conditions
Randomized
Interventions
BIOLOGICAL

Nasal Spray Lyophilized Live Attenuated Influenza Vaccine

0.2 ml/vial, 0.2ml/dose/per person

Sponsors
All Listed Sponsors
lead

Changchun BCHT Biotechnology Co.

INDUSTRY

NCT04825340 - To Explore a Bridging Index for the Effectiveness of the Clinical Trial | Biotech Hunter | Biotech Hunter